Preventing cognitive decline by reducing BP target (PCOT) : A randomized, pragmatic, multi-health systems clinical trial
Copyright © 2024. Published by Elsevier Inc..
BACKGROUND: Growing evidence suggests that intensive lowering of systolic blood pressure (BP) may prevent mild cognitive impairment (MCI) and dementia. However, current guidelines provide inconsistent recommendations regarding optimal BP targets, citing safety concerns of excessive BP lowering in the diverse population of older adults. We are conducting a pragmatic trial to determine if an implementation strategy to reduce systolic BP to <130 and diastolic BP to <80 mmHg will safely slow cognitive decline in older adults with hypertension when compared to patients receiving usual care.
METHODS: The Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is an embedded randomized pragmatic clinical trial in 4000 patients from two diverse health-systems who are age ≥ 70 years with BP >130/80 mmHg. Participants are randomized to the intervention arm or usual care using a permuted block randomization within each health system. The intervention is a combination of team-based care with clinical decision support to lower home BP to <130/80 mmHg. The primary outcome is cognitive decline as determined by the change in the modified Telephone Interview for Cognitive Status (TICS-m) scores from baseline. As a secondary outcome, patients who decline ≥3 points on the TICS-m will complete additional cognitive assessments and this information will be reviewed by an expert panel to determine if they meet criteria for MCI or dementia.
CONCLUSION: The PCOT trial will address the effectiveness and safety of hypertension treatment in two large health systems to lower BP targets to reduce risk of cognitive decline in real-world settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:138 |
|---|---|
| Enthalten in: |
Contemporary clinical trials - 138(2024) vom: 27. März, Seite 107443 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Giacona, John M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 03.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cct.2024.107443 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367103427 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367103427 | ||
| 003 | DE-627 | ||
| 005 | 20240304232249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cct.2024.107443 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM367103427 | ||
| 035 | |a (NLM)38219797 | ||
| 035 | |a (PII)S1551-7144(24)00017-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giacona, John M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preventing cognitive decline by reducing BP target (PCOT) |b A randomized, pragmatic, multi-health systems clinical trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 03.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: Growing evidence suggests that intensive lowering of systolic blood pressure (BP) may prevent mild cognitive impairment (MCI) and dementia. However, current guidelines provide inconsistent recommendations regarding optimal BP targets, citing safety concerns of excessive BP lowering in the diverse population of older adults. We are conducting a pragmatic trial to determine if an implementation strategy to reduce systolic BP to <130 and diastolic BP to <80 mmHg will safely slow cognitive decline in older adults with hypertension when compared to patients receiving usual care | ||
| 520 | |a METHODS: The Preventing Cognitive Decline by Reducing BP Target Trial (PCOT) is an embedded randomized pragmatic clinical trial in 4000 patients from two diverse health-systems who are age ≥ 70 years with BP >130/80 mmHg. Participants are randomized to the intervention arm or usual care using a permuted block randomization within each health system. The intervention is a combination of team-based care with clinical decision support to lower home BP to <130/80 mmHg. The primary outcome is cognitive decline as determined by the change in the modified Telephone Interview for Cognitive Status (TICS-m) scores from baseline. As a secondary outcome, patients who decline ≥3 points on the TICS-m will complete additional cognitive assessments and this information will be reviewed by an expert panel to determine if they meet criteria for MCI or dementia | ||
| 520 | |a CONCLUSION: The PCOT trial will address the effectiveness and safety of hypertension treatment in two large health systems to lower BP targets to reduce risk of cognitive decline in real-world settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Pragmatic Clinical Trial | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a AD: Alzheimer's disease | |
| 650 | 4 | |a BP: Blood pressure | |
| 650 | 4 | |a CDS: Clinical decision support | |
| 650 | 4 | |a MCI: Mild cognitive impairment | |
| 650 | 4 | |a PCT: Pragmatic clinical trial | |
| 650 | 4 | |a TICS-m: Telephone interview for cognitive status (modified) | |
| 700 | 1 | |a Bates, Brooke M |e verfasserin |4 aut | |
| 700 | 1 | |a Sundaram, Venkatraghavan |e verfasserin |4 aut | |
| 700 | 1 | |a Brinker, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Moss, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Paspula, Raja |e verfasserin |4 aut | |
| 700 | 1 | |a Kassa, Sentayehu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Song |e verfasserin |4 aut | |
| 700 | 1 | |a Basit, Mujeeb |e verfasserin |4 aut | |
| 700 | 1 | |a Burkhalter, Lorrie |e verfasserin |4 aut | |
| 700 | 1 | |a Cullum, C Munro |e verfasserin |4 aut | |
| 700 | 1 | |a Carlew, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Kelley, Brendan J |e verfasserin |4 aut | |
| 700 | 1 | |a Plassman, Brenda L |e verfasserin |4 aut | |
| 700 | 1 | |a Vazquez, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Vongpatanasin, Wanpen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contemporary clinical trials |d 2005 |g 138(2024) vom: 27. März, Seite 107443 |w (DE-627)NLM154869031 |x 1559-2030 |7 nnns |
| 773 | 1 | 8 | |g volume:138 |g year:2024 |g day:27 |g month:03 |g pages:107443 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cct.2024.107443 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 138 |j 2024 |b 27 |c 03 |h 107443 | ||